Teva ceo

Teva share price struggles to recover following $6 billion market loss

The financial results were actually positive, at the higher end of analysts' forecasts, but profit guidance for 2025 disappointed the market.

|BySHIRI HABIB-VALDHORN/GLOBES/TNS
Pills on health form
Teva building in Kfar Saba

US Supreme Court rejects Teva challenge to $235 million GSK award in patent dispute

Israel's Teva Pharmaceuticals and GlaxoSmithKline (GSK) have been disputing over this patent lawsuit since 2014.

|ByREUTERS
The CEO of Teva Pharmaceutical Industries Kare Schultz speaks during a news conference to discuss the company's 2019 outlooks in Tel Aviv, Israel February 19, 2019.

Israel's Teva Pharm to start paying US opioid settlement in 2023, says CEO

The US opioid crisis has caused more than 500,000 overdose deaths over the past two decades, including more than 80,000 in 2021 alone.

|ByZACHY HENNESSEY
The CEO of Teva Pharmaceutical Industries Kare Schultz speaks during a news conference to discuss the company's 2019 outlooks in Tel Aviv, Israel February 19, 2019

Teva's new migraine drug helps contain profit fall

Teva has reduced its spending by $2.5 billion since initiating the restructuring last year.

|ByREUTERS

Pharmaceutical giant Teva to lay off employees at Israel branches

Israeli media assesses that at some 300 employees would lose their jobs.

JULY 23, 2017BySHARON UDASIN
Teva Pharmaceutical Industries building in Jerusalem.

A taste of its own medicine?

Teva Pharmaceuticals, Israel’s biggest company, has seen its share price halved as generics eat at its profits, and leveraged buyouts have left it burdened with huge debts.

FEBRUARY 21, 2017BySHLOMO MAITAL
Erez Vigodman